Peritoneal dialysis patients (N=53) Average values* Minimum-maximum Reference values
Age, years 52 ± 12 19-75 -
Gender: men/women 28 (53%)/25 (47%)   -
Dialysis treatment duration, months 24 (15-51) 4-100 -
Observation period, months 60 (9-72) 1-72 -
All-cause mortality 24 (45%) - -
Cardiovascular mortality 19 (36%) - -
Active smoking 11 (21%) - -
Diabetes 12 (23%) - -
Hypertension 46 (87%) - -
Left ventricular ejection fraction, % 64 (60-66) 45-74 55-70
Left ventricular mass, g 244 ± 78 102-423 F: 67–162 M: 88–224
Left ventricular mass index, g/m2 138 ± 43 55-246 F: maximum to 110 M:maximum to 125
FRS, points 8 (5-10) 8-16 -
FRS, ten-year risk, % 10 (6-16) 1-37 -
BMI, kg/m2 25.2 ± 4.2 17.2-34.2 20-25
Systolic blood pressure, mmHg 149 ± 18 105-180 < 130
Diastolic blood pressure, mmHg 90 ± 12 60-115 < 80
Mean arterial pressure, mmHg 110 ± 11 87-133 75-100
Hemoglobin, g/dL 11.9 ± 1.7 7.7-15.3 12-17
Fibrinogen, g/L 6.0 ± 1.3 2.9-8.6 1.8-3.5
WBC, x103/µL 7.56 ± 2.44 2.77-12.36 4-10
hsCRP, mg/L 4.18 (1.29-11.40) 0.16-35.9 <3.17
Albumin, g/L 38 ± 5 20-47 35-50
Fasting glucose, mmol/L 4.7 (4.4-5.4) 3.4-15.4 3.3-5.6
Total cholesterol, mmol/L 5.54 ± 1.15 3.35-9.02 3.2-5.2
LDL-cholesterol, mmol/L 3.25 ± 0.93 1.45-6.35 0.2-3.4
HDL-cholesterol, mmol/L 1.41 ± 0.33 0.84-2.24 0.9-3.0
Triglycerides, mmol/L 1.95 ± 0.81 0.59-3.66 0.2-2.3
Ca, mmol/L 2.30 ± 0.22 1.59-2.67 2.1-2.4
Pi, mmol/L 1.78 ± 0.48 0.79-2.59 1.1-1.8
Ca x Pi, mmol2/L2 4.11 ± 1.27 1.81-5.99 < 4.4
iPTH, pg/mL 437 (198-836) 3-2474 12-72
FGF23, RU/mL 3013 (854-12015) 14.9-38798 no data
OPG, pmol/L 9.69 (8.44-13.18) 3.87-27.48 2.5-12.8 **
OC, ng/mL 65.2 (38.9-70.3) 10.6-72.5 F: 3.7-10.0 M: 3.4-9.1**
OPN, ng/mL 1475 (1038-1870) 559-3092 49.2-175.0**
CACS, Agatston units 92 (0-761) 0-4555 0-100
WCrCl, L/week/1.73 m2 66.7 (58.8-85.7) 43.2-213.8 > 45.0
* Number of patients (percent) is given for categorical variables; mean ± standard deviation or median (lower-upper quartile) for continuous variables with normal or non-normal distribution, respectively.
** Reference ranges established by manufacturer.
Table 1: Characteristics of the study group at the beginning of the study and data on mortality during follow-up period.